10 Hot Bio/Pharma Stocks on BPIQ’s Q2 Earnings Radar

6 days ago
2 min read

As Q2 earnings arrive, BPIQ has identified five Bio/Pharma stocks that stand out across our model portfolios, tracked hedge-fund positions, financial indicators and upcoming catalysts.

BPIQ’s Leading Five

$CYTK: Strongest Overall BPIQ Confirmation

CYTK is the only company on the list represented across three BPIQ model portfolios. Its developing MYQORZO launch and upcoming aficamten catalysts add to an active second-half calendar.

$RVMD: Leading Institutional Signal

RVMD has the highest tracked hedge-fund participation among the five, alongside substantial positions in the BPIQ Top 10A and Top 15 portfolios. Daraxonrasib’s accepted NDA remains the company’s central regulatory focus.

$MIRM: Commercial Growth Meets Upcoming Catalysts

MIRM combines an expanding commercial portfolio with multiple clinical and regulatory events. Its signals include BPIQ RunUp inclusion, 12 tracked hedge-fund holders and continued LIVMARLI growth.

$XENE: Strong Positioning Ahead of an NDA

XENE’s allocation in the BPIQ Top 15 increased by 34.3% to 9.4%. The company is also approaching an anticipated Q3 2026 NDA submission for azetukalner following positive Phase 3 results.

$CMPS: Multiple Signals Around COMP360

CMPS stands out for its late-stage regulatory progress. BPIQ flags COMP360 as a suspected mover, hedge-fund pick and high-management-interest program as its rolling NDA submission advances.

These five lead BPIQ’s earnings watchlist, but they are only half of the picture.

BPIQ table of Q4 2025 pre-deal hedge fund holdings for Terns, Centessa, and RAPT, with M&A dates, reported values, deal terms, and stock context.

Explore the full list of 10 Bio/Pharma stocks on BPIQ’s Q2 Earnings Radar. → Unlock Elite Subscription & Read the full Top 10 analysis

Explore BPIQ’s Model Portfolios

Model-portfolio positioning is one of several signals BPIQ used to build this earnings watchlist, alongside tracked hedge-fund participation, financial indicators, commercial progress and upcoming clinical and regulatory catalysts.

BPIQ’s model portfolios are built through a structured analysis of biotech hedge-fund consensus. They are not intended to predict post-earnings stock performance, but to provide a focused view of where specialist-investor conviction and BPIQ’s portfolio methodology identify notable opportunities.

Elite and APEX subscribers can explore current holdings and target allocations on BPIQ’s Model Portfolios page.

→ Explore BPIQ Model Portfolios

Not a subscriber yet? View BPIQ plans and subscribe

📊 Earnings Week Sale: 50% Off Elite Annual

Unlock BPIQ’s complete model portfolios, including current holdings and target allocations.

Offer valid August 5 through August 9, 2026 only.

Subscribe to Elite and Save 50%

BPIQ End-of-July Watchlist Sale banner, July 27 to August 2: 40% off APEX Annual and 50% off Elite Annual, featuring the Catalyst Screener, PDUFA Calendar, and Big Mover Stocks.

This article is not investment, tax, or legal advice. Please do your own diligence and seek advice from professional advisors representing your interests.

Article history:

First published 8/5/26 MD, RF